Open access
Sep 2026
Frailty is a mortality risk factor in tafamidis-treated patients with transthyretin cardiac amyloidosis.
Frailty assessed using the SEGA independently predicts mortality in ATTR-CM patients treated with tafamidis and improves prognostic stratification and may also help identify potentially modifiable vulnerabilities warranting personalized multidisciplinary care.
A. Broussier, A. Zaroui, M. Kharoubi et al.
· Amyloid: Journal of Protein... · 0 citations